Levodopa/carbidopa intraduodenal - AbbVie

Drug Profile

Levodopa/carbidopa intraduodenal - AbbVie

Alternative Names: ABT-SLV187; Carbidopa/levodopa intraduodenal; Duodopa; Duopa; LCIG; Levodopa/carbidopa intestinal gel

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator NeoPharma
  • Developer AbbVie
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 01 Dec 2016 AbbVie initiates enrolment in the DYSCOVER trial for Parkinson's disease (Late-stage disease) in USA and Spain(Intraduodenal) (NCT02799381)
  • 14 Jun 2016 AbbVie plans the phase III DYSCOVER trial for Parkinson's disease (Late-stage disease) in USA (Intraduodenal) (NCT02799381)
  • 19 Jun 2015 AbbVie initiates enrolment in the phase III INSIGHTS trial for Parkinson's disease (Late-stage disease) in Spain (EudraCT2014-004865-26)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top